Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rucaparib + nivolumab
- Development stage
- Unknown
- Lead developer
- Clovis Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Rucaparib + nivolumab is an investigational combination therapy studied for maintenance and treatment of several cancers, primarily advanced ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), and advanced biliary tract cancer. Rucaparib is an oral small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP), which is involved in DNA damage repair, leading to synthetic lethality in tumor cells with homologous recombination deficiency. Nivolumab is an intravenous monoclonal antibody that targets and inhibits the programmed death-1 (PD-1) receptor, enhancing anti-tumor immune responses by blocking tumor-mediated immune evasion. The combination has been evaluated to improve progression-free survival by synergistically increasing immune-mediated tumor cell death, but pivotal phase 3 studies such as ATHENA-COMBO have not met their primary efficacy endpoints for maintenance therapy in ovarian cancer. The regimen continues to be explored in other solid tumors, mainly as a post-chemotherapy maintenance or in homologous recombination-deficient settings[1][2][4][6][7].
- Brand names
- Rubraca + Opdivo
- Other names
- rucaparib and nivolumab
02
Targets
PARP2 (Poly (adp-ribose) polymerase 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on rucaparib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rucaparib + nivolumab.